Stay updated with breaking news from Multiple Sclerosis Ms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.
At the population level, small errors in blood pressure measurement can lead to the misclassification of millions of patients, one expert said.
Relatives and friends may not believe they're truly sick.
Autologous hematopoietic stem cell transplant is linked to less disability and lower relapse rates than other disease-modifying therapies for patients with secondary progressive multiple sclerosis.
Patients with chronic immune thrombocytopenia (ITP) fared better on intravenous efgartigimod (Vyvgart) than a placebo, but only 21.8% reached the primary endpoint of sustained platelet.